渗出型年龄相关性黄斑变性的形态学及视功能的研究

通过将渗出型年龄相关性黄斑变性(age-related macular degeneration,AMD)患者黄斑区OCT形态学检查及视觉电生理视功能检查相结合,探讨渗出型AMD的形态学改变与视功能改变之间的相互关系.方法 选取初次诊断为年龄相关性渗出型AMD的患者渗出组20例(30只眼)以及同年龄段正常对照组15名(30只眼),根据眼底及荧光造影检查将渗出组仅发生玻璃膜疣和脉络膜新生血管膜(CNV)的12只眼归为早期渗出组,并发视网膜下出血及渗出的18只眼归为渗出期组.对三组病人进行黄斑中心凹OCT检查及眼电生理检查.采用单因素方差分析检查结果.结果 (1)黄斑中心凹水平及垂直神经上皮层厚度:早期渗出组较正常组明显增厚(P＜0.05);渗出期组较正常组和早期渗出组明显增厚(P＜0.05).(2)眼电生理检查结果:暗适应ERG,OPS振荡电位以及P-VEP的检查结果表明,早期渗出组已出现了明显的视功能损害;渗出期组的视功能受损较早期渗出组严重.结论 渗出型AMD患者视功能的改变合并有视网膜神经上皮层的变厚,渗出期患者的黄斑区形态以及视网膜功能的改变比渗出早期更严重.     

Visual acuity and structural findings in old age-related macular degeneration

Background Although exudative age-related macular degeneration (AMD) leads to a substantial visual loss in most patients there is still significant variation in the end- stage visual acuity level. We analysed lesions in eyes with long-standing AMD in order to find contributing factors for this variation.Methods Sixty-one out of 121 patients examined for exudative AMD and still alive 4.8–9.2 (mean 6.8) years after the acute phase were re-examined. The lesion size, area of subretinal fibrosis, geographic atrophy, presence of a persistent exudative process, and shortest distance to normal looking retina were measured from digital fundus photographs taken at the re-examination and correlated with visual acuity.Results Lesion size, the presence of a continuing exudative process, or subretinal fibrosis were independent predictors for poor vision. Better vision in the other eye was connected with poor vision in the affected study eye.Conclusions In addition to lesion size, the presence of a continuing exudative process and subretinal fibrosis also have deleterious effects on long-term visual acuity after exudative AMD.Aila Riusala and Ilkka Immonen have full control of all primary data. They agree to allow Graefes Archive for Clinical and Experimental Ophthalmology to review the data if requested.The research was supported by grants to Aila Riusala from the Mary ja Georg C. Ehrnrooth, Paulo, Silmä- ja kudospankki- and Sokeain Ystävät Foundations, Helsinki, Finland and research funds of the Helsinki University Hospital, Helsinki, Finland.No proprietary or commercial interests were involved.     

Intravitreal bevacizumab for exudative age-related macular degeneration after multiple treatments

Background Photodynamic therapy with verteporfin (PDT) significantly reduces the risk of vision loss in patients with exudative age-related macular degeneration (AMD). Indocyanine green-mediated photothrombosis (IMP) and transpupillary thermotherapy (TTT) may also be beneficial for selective cases of exudative AMD. However, a substantial subset of patients responds poorly to these treatments. Intravitreal bevacizumab (IVB) has been recently used in the treatment of exudative AMD, showing both visual and anatomic improvement in the majority of cases. Methods This interventional retrospective case series reports the effects of IVB in 17 eyes with subfoveal neovascular AMD that had undergone repeated PDT (combined or not with triamcinolone acetonide) or PDT followed by either IMP or TTT with poor results. The main outcome measures were visual acuity and tomographic signs of intra/subretinal fluid, as well as central retinal thickness. Results Most patients received a single IVB injection. The mean follow-up was 4.47 months. The mean logMAR visual acuity changed from 1.17±0.40 to 1.06±0.44 (P=0.17). The mean central retinal thickness decreased from 404.05±245.26 to 280.23±143.14 μm (P=0.032). At the end of the study, lack of tomographic signs of intra/subretinal fluid was noted in four (23.5%) eyes. No ocular or systemic side effects were identified. Conclusions Short-term results with IVB for the treatment of exudative AMD have been promising. However, the chronic retinal and pigment epithelium changes frequently present in eyes that underwent multiple previous treatments may limit complete visual recovery. To our knowledge, this is the first report on the use of IVB for this particular group of AMD patients.     

Comparison of bevacizumab and ranibizumab in age-related macular degeneration:a systematic review and meta-analysis

AIM: To compare the effectiveness and safety between bevacizumab and ranibizumab in the treatment of age-related macular degeneration (AMD) through a systematic review and meta-analysis.METHODS:We performed a comprehensive search of randomized controlled trials (RCTs), non-RCTs, case-control and cohort studies that compared bevacizumab and ranibizumab using PubMed and the Cochrane Library. After the related data were extracted by two investigators independently, pooled weighted mean differences (WMDs) and risk ratios (RRs) with 95% confidence intervals (CIs) were estimated using a random-effects or a fixed-effects model.RESULTS:A total of four RCTs involving 1927 patients and eleven retrospective case series involving 2296 patients were included. For the primary outcomes, no significant differences were found between ranibizumab group and bevacizumab group in visual acuity (WMD:-0.04; 95%CI:-0.08 to 0.00; P=0.06), best corrected visual acuity (WMD:-0.05; 95%CI:-0.10 to 0.00; P=0.05), retina thickness (WMD:-4.69; 95%CI:-13.15 to 3.76; P=0.86) and foveal thickness (WMD:10.91; 95%CI:-14.73 to 36.56; P=0.40). The pooled analyses in the evaluation of safety showed that compared to bevacizumab, ranibizumab was associated with decreased risks of ocular inflammation (RR:0.45; 95% CI:0.23 to 0.89; P=0.02) and venous thrombotic events (RR:0.27; 95%CI:0.08 to 0.89; P=0.03). However, there were no significant differences observed in deaths (P=0.69) and arterial thromboembolic events (P=0.71) between the two groups.CONCLUSION:With equal clinical efficacy, ranibizumab was found to be associated with less adverse events compared to bevacizumab, indicating that ranibizumab might be a safer management.     

康柏西普治疗渗出性年龄相关性黄斑变性的临床观察

目的:分析康柏西普治疗渗出性年龄相关性黄斑变性(age-related macular degeneration,ARMD)的临床疗效.方法:选择2016-01/2017-01我院眼科收治的渗出性ARMD患者21例21眼为研究对象,所有患者均行玻璃体腔内注射康柏西普0.05mL(0.5mg).术后随访3mo,观察术前、术后1wk,1、3mo最佳矫正视力(best corrected visual acuity,BCVA)和黄斑中心凹视网膜厚度(central macular thickness,CMT)的变化.结果:术前和术后1wk,1、3mo患者BCVA分别为0.9±1.4、0.7±1.2、0.5±1.1、0.4±0.9.手术前后患者BCVA具有时间差异性(F=49.12,P<0.001).术后1wk,1mo分别与术前比较差异均无统计学意义(P>0.05);术后3 mo与术前比较,差异有统计学意义(P<0.05).术后3mo,视力改善19眼,视力不变2眼.术前、术后1wk,1、3 mo患者CMT分别为404.25±68.76、354.25±43.12、271.75±32.30、218.30±24.70μm.手术前后患者CMT具有时间差异性(F=2487.45,P<0.001).术后1wk,1、3 mo分别与术前比较,差异均有统计学意义(P<0.001).未发现与药物有关的全身不良反应及眼部并发症.结论:玻璃体腔内注射康柏西普治疗渗出性ARMD疗效显著.     

The methodological quality of systematic reviews comparing intravitreal bevacizumab and alternates for neovascular age related macular degeneration: A systematic review of reviews

Objective:

To systematically collate and evaluate the evidence from recent SRs of bevacizumab for neo-vascular age related macular degeneration.

Materials and Methods:

Literature searches were carried out in Medline, Embase, Cochrane databases for all systematic reviews (SRs) on the effectiveness of bevacizumab for neo-vascular age related macular degeneration, published between 2000 and 2013. Titles and abstracts were assessed against the inclusion/exclusion criteria using Joanna Briggs Institute (JBI) study eligibility form. Data was extracted using the JBI data extraction form. The quality of the SRs was assessed using JBI critical appraisal checklist for SRs. Decisions on study eligibility and quality were made by two reviewers; any disagreements were resolved by discussion.

Results:

Nine relevant reviews were identified from 30 citations, of which 5 reviews fulfilled the review''s inclusion criteria. All 5 reviews showed bevacizumab to be effective for neovascular AMD in the short-term when used alone or in combination with PDT or Pegaptanib. The average quality score of the reviews was 7; 95% confidence interval 6.2 to 7.8 (maximum possible quality score is 10). The selection and publication bias were not addressed in all included reviews. Three-fifth of the reviews had a quality score of 7 or lower, these reviews had some methodological limitations, search strategies were only identified in 2 (40%) reviews, independent study selection and quality assessment of included studies (4 (80%)) were infrequently performed.

Conclusion:

Overall, the reviews on the effectiveness of intravitreal/systemic bevacizumab for neovascularage-related macular generation (AMD) received good JBI quality scores (mean score = 7.0 points), with a few exceptions. The study also highlights the suboptimal reporting of SRs on this topic. Reviews with poor methodology may limit the validity of the reported results; hence efforts should be made to improve the design, reporting and publication of SRs across all journals.     

雷珠单抗治疗重度视力损害渗出型年龄相关性黄斑变性患者的疗效观察

目的观察玻璃体腔注射雷珠单抗治疗重度视力损害渗出型年龄相关性黄斑变性(AMD)患者的疗效。方法回顾性分析在我院确诊为渗出型AMD、最佳矫正视力(BCVA)<0.05并接受雷珠单抗玻璃体腔注射的46例患者(47只眼)的临床资料。所有患者均行玻璃体腔注射雷珠单抗治疗,治疗后随访1~8个月,平均随访(4.09±2.25)个月。对比分析玻璃体腔注射雷珠单抗治疗前后BCVA、黄斑中心视网膜厚度(CRT)、病变最厚处视网膜厚度(MRT)的变化及不良反应的发生情况。结果至末次随访时,47只眼中,视力提高29只眼,占61.7%;视力稳定15只眼,占31.9%;视力下降3只眼,占6.4%。治疗后,平均CRT由治疗前的(301.30±84.57)μm降低为(211.27±87.03)μm;与治疗前相比,平均CRT下降(90.03±33.99)μm,差异有统计学意义(t=4.336,P<0.01);MRT由(529.04±174.63)μm降低为(421.86±95.78)μm;与治疗前相比,平均MRT下降(107.17±42.46)μm,差异有统计学意义(t=3.984,P<0.01)。结论雷珠单抗治疗重度视力损害渗出型AMD患者具有较好的疗效。     

玻璃体腔内注射贝伐单抗后视网膜电图明视负向反应改变

目的研究玻璃体腔内注射贝伐单抗后渗出性年龄相关性黄斑变性（AMD）、增生性糖尿视网膜病变（PDR）患者视力、闪光视网膜电图（ERG）明视负向反应（PhNR）和黄斑神经上皮层厚度（CRT）变化。设计回顾性、自身对照研究。研究对象8例渗出性AMD患者（9眼）和3例PDR患者（3眼）。方法患者于表面麻醉下给予1．25mg（0．05ml）贝伐单抗玻璃体腔内注射。患者治疗前及治疗后1个月检查EDTR视力、眼压、视野、荧光素眼底血管造影、相干光断层扫描和闪光ERG。主要指标PhNR振幅、视力和CRT。结果治疗前后CRT显著下降（n=12,P=0．008）,但PhNR振幅和视力变化不显著（n=12,P=0．153）。CRT与PHNR振幅（r=0．294,P=0．145）、CRT与视力无显著相关性（r=0．358,P=0．073）。结论玻璃体腔内单次注射贝伐单抗可减轻渗出性AMD和PDR患者的黄斑水肿,但对视功能的改善需要进一步的观察。（跟科,2009,18：243—246）     

玻璃体内注射康柏西普对渗出性老年性黄斑变性患者脉络膜厚度的影响

目的　观察玻璃体内注射康柏西普对渗出性老年性黄斑变性（ａｇｅ-ｒｅｌａｔｅｄｍａｃｕｌａｒｄｅｇｅｎｅｒａｔｉｏｎ,ＡＭＤ）患者脉络膜厚度（ｃｈｏｒｏｉｄａｌｔｈｉｃｋｎｅｓｓ,ＣＴ）的影响。方法　确诊为渗出性ＡＭＤ患者４２例４２眼,分为典型ＡＭＤ（ｔｙｐｉｃａｌ-ＡＭＤ,ｔＡＭＤ）组和息肉样血管病变（ｐｏｌｙｐｏｉｄａｌｃｈｏｒｏｉｄａｌｖａｓｃｕｌｏｐａｔｈｙ,ＰＣＶ）组,均行３＋ＰＲＮ方案的玻璃体内注射康柏西普治疗。采用光学相干断层扫描的增强深度成像技术测量治疗前及初次治疗后１个月、２个月、３个月、６个月治疗眼及对侧眼中心凹下脉络膜厚度（ｓｕｂｆｏｖｅａｌｃｈｏｒｏｉｄａｌｔｈｉｃｋｎｅｓｓ,ＳＦＣＴ）及距离中心凹１ｍｍ的鼻侧和颞侧ＣＴ,对比分析康柏西普治疗前后的ＣＴ变化。结果　渗出性ＡＭＤ患眼玻璃体内注射康柏西普后１个月、２个月、３个月、６个月ＳＦＣＴ分别为（２２３．５５±３０．７１）μｍ、（２２１．５２±３３．３７）μｍ、（２１４．４３±３１．８１）μｍ、（２１４．９３±３１．４１）μｍ;治疗后６个月鼻侧ＣＴ从（２２５．４０±４３．９７）μｍ减少至（２０５．７１±４２．２０）μｍ,颞侧ＣＴ从（２３５．２１±４７．２２）μｍ降至（２０３．５２±３９．１５）μｍ;与基线相比,差异均具有统计学意义（均为Ｐ＜０．００１）。其中,ｔＡＭＤ组ＳＦＣＴ从（２３４．０６±４１．０４）μｍ减至（２０９．１９±３２．１４）μｍ,ＰＣＶ组从（２７４．６０±２７．７３）μｍ减至（２３３．３０±２１．０８）μｍ,各随访时间点所测ＳＦＣＴ与基线时相比差异均具有统计学意义（均为Ｐ＜０．０５）,而对侧正常眼６个月各时间点ＳＦＣＴ无明显改变。结论　玻璃体内注射康柏西普会引起渗出型ＡＭＤ（ｔＡＭＤ和ＰＣＶ）ＣＴ降低。     

Comparative role of intravitreal ranibizumab versus bevacizumab in choroidal neovascular membrane in age-related macular degeneration

Context:

Ranibizumab and bevacizumab are used widely for treating patients with choroidal neovascular membrane (CNVM) secondary to age-related macular degeneration (AMD).

Aims:

To determine and compare the efficacy and safety of intravitreal ranibizumab and bevacizumab in treatment of CNVM due to AMD.

Settings and Design:

Prospective comparative case series carried out in an eye institute and eye department of a hospital in Kolkata, India.

Materials and Methods:

One hundred and four eyes with CNVM due to AMD were randomized into two groups. Group A (n=54; 24 occult) received monthly intravitreal ranibizumab injections (0.5 mg in 0.05 ml) and Group B (n=50; 22 occult) received monthly bevacizumab injections (1.25 mg in 0.05 ml) for 3 consecutive months and then as per study criteria. Data analysis done using SPSS software. P-value of <0.05 was considered statistically significant.

Results:

The mean best corrected visual acuity (BCVA) in the ranibizumab group increased from 58.19 Early Treatment Diabetic Retinopathy Study (ETDRS) letters at baseline to 64 ETDRS letters at month 3 (P<0.001). In bevacizumab group mean BCVA increased from 56.80 to 61.72 ETDRS letters at month 3 (P<0.001). At the end of 18 months, there was no statistically significant difference between groups A and B with respect to change in BCVA (P=0.563) or central macular thickness (CMT; P=0.281), as measured by optical coherence tomography (Stratus OCT 3000). No significant sight-threatening complications developed.

Conclusions:

Ranibizumab and bevacizumab are equally safe and efficacious in treating CNVM due to AMD.     

Ranibizumab治疗湿性年龄相关性黄斑变性的系统综述

年龄相关性黄斑变性（AMD）可导致严重的视力丧失,脉络膜新生血管（CNV）是其主要的致盲原因,血管内皮生长因子（VEGF）在CNV的形成过程中起着至关重要的作用。Ranibizumab是一种重组的人源化抗VEGF单克隆抗体片段,能够抑制新生血管形成,减少血管渗漏。国内外多项研究证实玻璃体腔内注射ranibizumab治疗湿性AMD具有一定的疗效,为ranibizumab的临床应用提供了高等级的临床试验证据。Ranibizumab治疗湿性AMD的最佳时机为治疗的起始阶段,其最佳治疗方案为每月注射1次,连续3个月,之后每月注射1次进行维持治疗。维持期的治疗应每月监测病情的动态变化,光学相干断层扫描（OCT）、荧光素眼底血管造影（FFA）、视力等是主要的检测指标,对调整治疗方案起指导作用。维持阶段也可采取个体化治疗或与光动力疗法（PDT）的联合疗法,以适当减少注射次数和频率。系统检索和总结ranibizumab治疗湿性AMD的文献资料．可从循证医学的角度为ranibizumab的临床应用提供证据支持。     

Retinal pigment epithelial tears after intravitreal bevacizumab injection for exudative age-related macular degeneration

Purpose: To determine the incidence of and the risk factors for the development of retinal pigment epithelial (RPE) tears after intravitreal bevacizumab (Avastin) injection for the treatment of exudative age‐related macular degeneration (AMD). Methods: A retrospective, multicentre, consecutive interventional case series of all patients with subfoveal exudative AMD treated with intravitreal bevacizumab between August 2005 and April 2007. The main outcome measures were pre‐ and post‐RPE tear visual acuity and choroidal neovascular membrane lesion types, incidence of tears and time from first injection until development of the tear. Results: A total of 920 eyes with exudative AMD were treated with intravitreal bevacizumab. Fifteen eyes from 15 patients developed a RPE tear for an incidence of 1.6%. The average patient age was 79 years. Fourteen of the fifteen eyes (93%) had an occult subfoveal choroidal neovascular membrane. Forty‐seven per cent (7/15) of the RPE tears occurred within the first 6 weeks of treatment, and all tears occurred within the first 18 weeks of treatment initiation. The mean pre‐injection visual acuity was 20/100 with a mean post‐tear visual acuity of 20/200. In all 10 eyes in which the tear involved the fovea, the final visual acuity was poor. Six of the 15 eyes continued with bevacizumab/ranibizumab (Lucentis) injections after tear development, and four of these six eyes continued to have visual improvement. Conclusion: RPE tears occur after intravitreal bevacizumab injections for exudative AMD in approximately 1.6% of eyes and can cause severe vision loss. Maintenance of therapy may help preserve vision after RPE tear development.     

渗出型老年黄斑变性的吲哚菁绿血管造影图像特征

目的 探讨渗出型老年黄斑变性(AMD)吲哚菁绿血管造影(ICGA)与荧光素眼底血管造影(FFA)比较的图像特征。方法 对52例65眼渗出型AMD患者进行了眼底彩色照相、FFA和ICGA检查。结果 渗出型AMD的65眼中，ICGA诊断为典型性脉络膜新生血管(CNV)有33跟．占50．8％，FFA诊惭为典型性CNV有8眼，占11．6％；FFA诊断为隐匿性CNV的35眼中，ICGA诊断为边界清楚或久清楚的斑状CNV有22眼；合并黄斑出血39眼中，FFA不能发现的CNV而ICGA能发现共5眼；FFA诊断为痕痕染色的7眼中，有2眼有ICGA中发现CNV；ICGA发现CNV的供养血管(feeding vessel)有3眼。结论 ICGA比FFA发现CNV诊断率高，准确地显示黄斑出血所掩盖的CNV，ICCA有助丁发现CNV的供养血管。     

Intravitreal bevacizumab (Avastin) for occult choroidal neovascularization in age-related macular degeneration

Background The purpose of the study is to report data on short-term safety of intravitreal bevacizumab treatment and its effect on visual function, central retinal thickness, and angiographical changes of occult choroidal neovascularization due to age-related macular degeneration. Methods A consecutive interventional case series of 30 patients with active subfoveal occult choroidal neovascularization secondary to age-related macular degeneration was followed after one intravitreal injection of 1.25 mg bevacizumab at baseline and subsequent injections following standardized criteria. At baseline and follow-up visits patients had visual acuity assessment, intraocular pressure measurement, fluorescein angiography, and optical coherence tomography imaging. Results No serious ocular or systemic adverse events were identified. A significant increase of intraocular pressure or signs of retinal toxicity or endophthalmitis were not detected in any patient. Optical coherence tomography revealed significant decrease (p < 0.001) in central retinal thickness after 1 week, 4 weeks, and 12 weeks, respectively. Fluorescein leakage decreased within 1 week and improvement was maintained at week 12 in the majority of patients. Visual acuity improved or remained stable in 29 of 30 patients; improvement of 3 or more lines was seen in 14 of 30 patients; one patients showed improvement of 6 lines. No patient had severe vision loss of 6 lines or more; moderate vision loss of 3 lines was seen in one patient. Re-injections of bevacizumab according to standard criteria were performed one to two times during the follow-up period of 12 weeks with a re-injection interval of 4 to 18 weeks (median 8 weeks). Conclusions Short-term results suggest that intravitreal injection of bevacizumab is well tolerated and for the majority of patients with occult choroidal neovascularization in AMD results in improvement of visual acuity, decrease in central retina thickness, and reduction of angiographic leakage of the lesion. Bevacizumab as intravitreal treatment may provide a novel therapeutic option for selected patients with exudative AMD. Randomized prospective multicenter trials seem justified to further evaluate long term effects and impact of intravitreal bevacizumab on different subtypes of AMD compared to established therapies.     

Treatment of dry age-related macular degeneration: A review

Age-related macular degeneration is a global disease with a significant societal impact. The advent of anti-vascular endothelial growth factor therapy (anti-VEGF) has revolutionised the treatment of neovascular age-related macular degeneration (nAMD). Dry age-related macular degeneration (dAMD) is being investigated for possible therapeutic options. The therapeutic categories undergoing clinical trials include complement pathway inhibitors, visual cycle modulators, reduction of toxic byproducts, antioxidative therapy, neuroprotective agents, laser therapy, surgical options, gene therapy, stem cell therapy, and miscellaneous treatments. Two intravitreal anti-complement factors (pegcetacoplan and avacincaptad pegol) have recently shown phase 3 clinical trial evidence of a reduction in the growth of geographic atrophy. In this review, we provide an update on treatment options currently undergoing clinical research trials for the management of dAMD and preventing the progression of Geographic Atrophy (GA).     

渗出性年龄相关性黄斑变性患者的屈光状态

目的 探讨渗出性年龄相关性黄斑变性（AMD）患者与非AMD健康者屈光状态的差异。设计 病例对照研究。 研究对象 筛选并纳入136例渗出性AMD患者具有屈光状态记录的247眼,其中154只患眼作为渗出性AMD组,包括34例双眼渗出性AMD患者的67眼及102例单眼渗出性AMD患者的87眼。选取北京德胜社区非AMD正常受试者中与渗出性AMD患者年龄、性别匹配的136例,纳入具有屈光状态的242眼作为对照组。方法 采用电脑验光后显然验光的方法测量纳入眼的屈光度。远视标准定义为>+0.5 D。比较两组患者的屈光状态。主要指标 屈光状态与屈光度。结果 渗出性AMD组远视72眼（46.7%）,屈光度（四分位数间距）为+0.50（-0.38,+1.25）D。对照组远视74眼（30.6%）,屈光度为+0.13（-1.13,+0.84）D。渗出性AMD组较对照组远视眼比例高（P<0.001）,渗出性AMD组较对照组更倾向于远视（P<0.001）。结论 渗出性AMD患者较非AMD健康者可能更倾向于发生远视,且远视的度数更高。（眼科, 2014, 23： 99-102）     

玻璃体腔注射Bevacizumab(Avastin)治疗湿性ARMD临床观察

目的:观察玻璃体腔注射bevacizumab(avastin)治疗湿性年龄相关性黄斑变性(age-related macular degeneration,ARMD)的疗效和安全性。方法:对22例22眼湿性ARMD患者行玻璃体腔注射bevacizumab1.25mg,间隔6wk再注射1次,第12wk对检查发现黄斑区水肿或渗漏明显的再注射1次。随访6mo,术后第1wk;1,3,6mo行视力、眼压、裂隙灯、间接检眼镜及光学相干断层扫描(optical coherence tomography,OCT)检查,第3,6mo行荧光素眼底血管造影(fundusfluorescence angiography,FFA)、彩色眼底照相检查,分析治疗前后患者平均视力及黄斑中心视网膜厚度(centralmacular thickness,CMT)的改变。结果:至第6mo随访,平均视力较治疗前有所提高,平均CMT比治疗前减少92.59μm,均有显著意义;FFA显示黄斑区渗漏均消失或明显减轻。除4例局部球结膜下出血,没有观察到其他不良反应。结论:玻璃体腔注射bevacizumab能够提高湿性ARMD患者的视力,减轻黄斑水肿;重复注射可以巩固疗效,减少复发。长期效果和安全性还需要更多病例和更长随访观察时间来评估。     

Retinal pigment epithelial tears after intravitreal bevacizumab injection for exudative age-related macular degeneration

We report a series of retinal pigment epithelial (RPE) tears after intravitreal bevacizumab therapy for choroidal neovascularization associated with age-related macular degeneration (ARMD). Retinal pigment epithelial tears were estimated to occur at an incidence of 1.6% in this patient population at our institution. Ophthalmologists should be aware of this rare but serious finding associated with exudative macular degeneration therapy.